Lilly and Hims & Hers Agree to Sell Zepbound and Foundayo Directly on Telehealth Platform
Eli Lilly and Company and Hims & Hers Health said Nov. 6, 2026, that patients on the Hims & Hers telehealth platform can now buy Lilly's obesity medicines Zepbound and Foundayo at Lilly's standard self-pay prices without leaving the platform. The agreement, announced from Indianapolis, starts at $149 a month for the Foundayo tablet and $299 a month for the Zepbound injection, and it commits Hims & Hers to never selling compounded copies of Lilly's GLP-1 medicines.
Key developments
- Eligible patients who receive a prescription from a licensed provider on the Hims & Hers platform can pay Lilly's self-pay prices for Zepbound (tirzepatide) and Foundayo (orforglipron) and have the medicine shipped to their home.
- Self-pay pricing starts at $149 per month for once-daily oral Foundayo and $299 per month for once-weekly injectable Zepbound, the same prices available to any self-pay patient.
- Hims & Hers said it has never offered compounded copies of Lilly's GLP-1 medicines and committed not to do so in the future.
- Both companies committed to protecting independent clinical decision-making, so providers on the platform continue to prescribe the treatment they judge appropriate for each patient.
- Before the deal, Hims & Hers patients seeking Lilly drugs had to leave the site for LillyDirect, Lilly's own cash-pay platform, according to Reuters.
Industry background
Zepbound is a once-weekly injection approved in doses from 2.5 mg to 15 mg for chronic weight management in adults with obesity, or with overweight and weight-related medical problems, and for moderate-to-severe obstructive sleep apnea in adults with obesity. Foundayo is a once-daily oral tablet, approved in strengths from 0.8 mg to 17.2 mg, for weight management in adults with obesity or overweight with weight-related conditions. Both carry warnings about possible thyroid tumors and should not be used by people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
The partnership reverses a public distance between the two companies. In April 2025, Lilly issued a statement saying it had no affiliation with Hims & Hers, at a time when telehealth platforms were selling compounded versions of GLP-1 drugs during supply shortages. Lilly then directed self-pay patients to LillyDirect, where self-pay Zepbound then started at $349 per month. The new arrangement brings the companies together and lowers the entry price for Zepbound on the platform to $299.
Novo Nordisk, Lilly's main rival in obesity medicine, has sold Wegovy and Ozempic through Hims & Hers since March, Reuters reported, after earlier suing the company over compounded versions of its drugs. Reuters also reported that Lilly launched Foundayo in April, about three months after Novo's Wegovy pill reached the market.
Industry implications
The deal shows how cash-pay telehealth has become a primary sales channel for obesity drugs rather than a side route. Lilly told Reuters that 40% to 45% of Zepbound sales come through self-pay channels. For a product with that profile, each step between a prescription and a purchase matters. Ilya Yuffa, president of Lilly USA and Global Customer Capabilities, said in the release that Lilly is looking for ways of meeting patients where they already are, and he told Reuters that every extra step raises the chance a patient abandons the purchase.
The no-compounding commitment is equally important. Drugmakers have pushed pharmacies and online sellers away from compounded semaglutide and tirzepatide since the shortages of those drugs ended. By tying platform access to a written pledge, Lilly turns a regulatory and legal dispute into a commercial term. Other brand owners may seek similar clauses as they negotiate with telehealth companies.
For payers and employers, the arrangement adds another lever. Reuters reported analyst views that Hims & Hers could benefit next year if employers drop coverage of weight-loss drugs, pushing more patients toward direct purchase. That would shift more of the cost of obesity treatment onto consumers and make published self-pay prices a central feature of the category.
Competitive and supply chain implications
With both Lilly and Novo now selling directly through Hims & Hers, the platform becomes a side-by-side shelf for the two leading GLP-1 franchises. Reuters reported that Novo's Wegovy pill starts at $149 a month on the platform and the Wegovy pen at $199, so pricing for the oral products now matches at the entry dose while the injectables differ. Providers on the platform will be choosing between oral and injectable options from both companies, which puts the focus on tolerability, dosing convenience and supply reliability.
For Lilly's supply chain, the agreement adds demand through a channel that ships medicines directly to patients' homes. Lilly has spent heavily on new U.S. manufacturing for incretin medicines, and steady direct-to-patient volume through large platforms can make production planning more predictable than retail pharmacy demand. For Hims & Hers, the arrangement replaces any reliance on compounded GLP-1 supply with branded product sourced from the manufacturer.
The deal also raises the bar for smaller telehealth companies that still rely on compounded products. Platforms without manufacturer agreements may face more legal pressure and a weaker price argument as branded self-pay prices fall.
Regional implications
The agreement applies to the U.S. self-pay market, where direct-to-consumer telehealth and manufacturer cash-pay programs have grown fastest. Patients in states with limited employer or Medicaid coverage for obesity drugs stand to gain the most from a lower and more visible price. Home delivery also widens access for patients in rural areas who have fewer obesity specialists nearby.
Outside the United States, the deal has no direct effect, because pricing, prescribing and telehealth rules differ by country. However, the model of a manufacturer setting one published self-pay price and offering it through third-party platforms could inform how Lilly and its rivals approach other markets with large self-pay populations.
Credence Research analysis
The Lilly and Hims & Hers agreement reflects a broader shift in how obesity medicines reach patients. Manufacturers now set the self-pay price themselves and distribute it through any channel willing to accept their terms, including platforms they once publicly distanced themselves from. The key terms here are price parity with LillyDirect and a ban on compounded copies, which suggests Lilly is prioritizing control of price and product integrity over channel exclusivity. That approach lets Lilly widen reach without discounting below its own published prices.
The bigger question is how quickly the oral segment develops. With Foundayo and the Wegovy pill both starting at $149 a month on the same platform, patients and prescribers will compare the two directly, and real-world persistence data will shape demand more than list prices. Telehealth platforms that can show consistent dosing, side-effect management and refill rates will hold stronger positions in future negotiations with drugmakers.
What comes next
- Rollout of Zepbound and Foundayo ordering on the Hims & Hers platform, including how quickly consultations convert to prescriptions.
- Whether Lilly signs similar agreements with other telehealth companies that commit to avoiding compounded products.
- Any change in Lilly or Novo self-pay pricing for oral and injectable GLP-1 medicines in response to platform competition.
- Employer and insurer coverage decisions for 2027 plan years, which could push more patients toward self-pay channels.
- Updates on the agreement in the next quarterly reports from Lilly and Hims & Hers.
Sources
- Eli Lilly and Company: Lilly and Hims & Hers expand access to FDA-approved Lilly medicines (Nov. 6, 2026)
- Hims & Hers Health: Lilly and Hims & Hers expand access to FDA-approved Lilly medicines (Nov. 6, 2026)
- Eli Lilly and Company: Statement on Hims & Hers (April 1, 2025)
- Reuters via Investing.com: Lilly to sell obesity drugs directly on Hims & Hers site (Nov. 6, 2026)
Image: Eli Lilly Corporate Center in Indianapolis, by Momoneymoproblemz via Wikimedia Commons, CC BY-SA 4.0. Cropped and edited by Credence Research.
About the Author
Senior News Editor at Credence Research Inc